Phage therapy pharmacology. Phage cocktails

Advances in Applied Microbiology

Volumn 78, Issue , 2012, Pages 1-23

  Chan, Benjamin K ^a   Abedon, Stephen T ^b  

^a UNIVERSITY OF UTAH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Bacteriophage; Phage performance; Phage therapy; Pharmacokinetics; Pharmacology

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM ISOLATE; BACTERIUM MUTANT; BIOFILM; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; HOST RANGE; LABORATORY TEST; MIXED INFECTION; MONOPHAGE; MONOVALENCE; NONHUMAN; PHARMACODYNAMICS; POLYPHAGE; POLYVALENCE; PRODUCTIVITY; HUMAN;

BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; HUMANS;

EID: 84856507333     PISSN: 00652164     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394805-2.00001-4     Document Type: Chapter

References (68)

1. A Subscriber (1806). To the editor of the balance. The Balance, and Columbian Repository. V, 146.
2. Abedon S.T. Lysis and the interaction between free phages and infected cells. The Molecular Biology of Bacteriophage T4 1994, 397-405. ASM Press, Washington, DC. J.D. Karam (Ed.).
3. Abedon S.T. Impact of phage properties on bacterial survival. Contemporary Trends in Bacteriophage Research 2009, 217-235. Nova Science Publishers, Hauppauge, New York. H.T. Adams (Ed.).
4. Abedon S.T. Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog. Dis. 2009, 6:807-815.
5. Abedon S.T. Bacteriophages and biofilms. Biofilms: Formation, Development and Properties 2010, 1-58. Nova Science Publishers, Hauppauge, New York. W.C. Bailey (Ed.).
6. Abedon S.T. Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques 2011, Nova Science Publishers, Hauppauge, New York.
7. Abedon S.T. Lysis from without. Bacteriophage 2011, 1:46-49.
8. Abedon S. Phage therapy pharmacology: Calculating phage dosing. Adv. Appl. Microbiol. 2011, 77:1-40.
9. Abedon S.T. Bacteriophages as drugs: The pharmacology of phage therapy. Phage Therapy: Current Research and Applications 2012, Caister Academic Press, Norfolk, UK. J. Borysowski, R. Miêdzybrodzki, A. Górski (Eds.).
10. Abedon S.T., Thomas-Abedon C. Phage therapy pharmacology. Curr. Pharm. Biotechnol. 2010, 11:28-47.
11. Abedon S.T., Kuhl S.J., Blasdel B.G., Kutter E.M. Phage treatment of human infections. Bacteriophage 2011, 1:66-85.
12. Ackermann H.W. Phage or Phages. Bacteriophage 2011, 1:52-53.
13. Ackermann H.-W., DuBow M.S. Viruses of Prokaryotes, Volume 1, General Properties of Bacteriophages 1987, CRC Press, Boca Raton, FL.
14. Balogh B., Jones J.B., Iriarte F.B., Momol M.T. Phage therapy for plant disease control. Curr. Pharm. Biotechnol. 2010, 11:48-57.
15. Borchelt M. Potential side-effects and interactions in multiple medication in elderly patients: methodology and results of the Berlin Study of Aging. Z. Gerontol. Geriatr. 1995, 28:420-428.
16. Bruttin A., Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 2005, 49:2874-2878.
17. Cairns B.J., Payne R.J.H. Bacteriophage therapy and the mutant selection window. Antimicrob. Agents Chemother. 2008, 52:4344-4350.
18. Carlson K. Working with bacteriophages: Common techniques and methodological approaches. Bacteriophages: Biology and Application 2005, 437-494. CRC Press, Boca Raton, FL. E. Kutter, A. Sulakvelidze (Eds.).
19. Carlton R.M., Noordman W.H., Biswas B., de Meester E.D., Loessner M.J. Bacteriophage P100 for control of Listeria monocytogenes in foods: Genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul. Toxicol. Pharmacol. 2005, 43:301-312.
20. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2003, 2:624-634.
21. Chan B.K., Abedon S.T. Bacteriophage adaptation, with particular attention to issues of phage host range. Bacteriophages in Dairy Processing 2011, Nova Science Publishers, Hauppauge, New York. A. Quiberoni, J. Reinheimer (Eds.).
22. Curtright A.J., Abedon S.T. Phage therapy: Emergent property pharmacology. J. Bioanal. Biomed 2011, S6.
23. D'Hérelle F. Sur un microbe invisible antagoniste des bacilles dysentériques. C. R. Acad. Sci. D 1917, 165:373-375.
24. d'Hérelle F. On an invisible microbe antagonistic to dysentery bacilli. Bacteriophage 2011, 1:3-5.
25. de Vries G.E., Raymond C.K., Ludwig R.A. Extension of bacteriophage lambda host range: Selection, cloning, and characterization of a constitutive lambda receptor gene. Proc. Natl. Acad. Sci. USA 1984, 81:6080-6084.
26. Fischbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Science 2009, 325:1089-1093.
27. Fortuna W., Miedzybrodzki R., Weber-Dabrowska B., Górski A. Bacteriophage therapy in children: Facts and prospects. Med. Sci. Monit. 2008, 14:RA126-RA132.
28. Geddes J.R., Goodwin G.M., Rendell J., Azorin J.M., Cipriani A., Ostacher M.J., Morriss R., Alder N., Juszczak E. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial. Lancet 2010, 375:385-395.
29. Gill E.E., Brinkman F.S. The proportional lack of archaeal pathogens: Do viruses/phages hold the key?. Bioessays 2011, 33:248-254.
30. Gill J.J., Hyman P. Phage choice, isolation and preparation for phage therapy. Curr. Pharm. Biotechnol. 2010, 11:2-14.
31. Gill J.J., Young R. Therapeutic applications of phage biology: History, practice and recommendations. Emerging Trends in Antibacterial Discovery: Answering the Call to Arms 2011, Caister Academic Press, Norfolk, UK. A.A. Miller, P.F. Miller (Eds.).
32. Goodridge L.D. Designing phage therapeutics. Curr. Pharm. Biotechnol. 2010, 11:15-27.
33. Górski A., Miedzybrodzki R., Borysowski J., Weber-Dabrowska B., Lobocka M., Fortuna W., Letkiewicz S., Zimecki M., Filby G. Bacteriophage therapy for the treatment of infections. Curr. Opin. Investig. Drugs 2009, 10:766-774.
34. Guttman B., Raya R., Kutter E. Basic phage biology. Bacteriophages: Biology and Application 2005, 29-66. CRC Press, Boca Raton, FL. E. Kutter, A. Sulakvelidze (Eds.).
35. Hagens S., Loessner M.J. Bacteriophage for biocontrol of foodborne pathogens: Calculations and considerations. Curr. Pharm. Biotechnol. 2010, 11:58-68.
36. Hawkins C., Harper D., Burch D., Anggard E., Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet. Microbiol. 2010, 145:309-313.
37. Hawrelak J.A., Myers S.P. The causes of intestinal dysbiosis: A review. Altern. Med. Rev. 2004, 9:180-197.
38. Hyman P., Abedon S.T. Practical methods for determining phage growth parameters. Methods Mol. Biol. 2009, 501:175-202.
39. Hyman P., Abedon S.T. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 2010, 70:217-248.
40. Johansen H.K., Jensen T.G., Dessau R.B., Lundgren B., Frimodt-Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vitro. J. Antimicrob. Chemother. 2000, 46:973-980.
41. Ketter T.A. Treating bipolar disorder: Monotherapy versus combination therapy. J. Clin. Psychiatry 2009, 70:e42.
42. Kutter E. Phage therapy: Bacteriophages as natural, self-limiting antibiotics. Textbook of Natural Medicine 2005, 1147-1161. 3rd edn. W. Pizzorno (Ed.).
43. Kutter E.M. Bacteriophage therapy: Past and present. Encyclopedia of Microbiology 2009, 258-266. Elsevier, Oxford. M. Schaecter (Ed.).
44. Kutter E., De Vos D., Gvasalia G., Alavidze Z., Gogokhia L., Kuhl S., Abedon S.T. Phage therapy in clinical practice: Treatment of human infections. Curr. Pharm. Biotechnol. 2010, 11:69-86.
45. Kysela D.T., Turner P.E. Optimal bacteriophage mutation rates for phage therapy. J. Theor. Biol. 2007, 249:411-421.
46. Leszczynski P., Weber-Dabrowska B., Kohutnicka M., Luczak M., Górecki A., Górski A. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker-A case report. Folia Microbiol. 2008, 51:236-238.
47. Levin B.R., Bull J.J. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2004, 2:166-173.
48. Loc-Carrillo C., Abedon S.T. Pros and cons of phage therapy. Bacteriophage 2011, 1:111-114.
49. McVay C.S., Velasquez M., Fralick J.A. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 2007, 51:1934-1938.
50. Miedzybrodzki R., Fortuna W., Weber-Dabrowska B., Gorski A. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig. Med. Dosw. (Online) 2007, 61:461-465.
51. Morona R., Henning U. Host range mutants of bacteriophage Ox2 can use two different outer membrane proteins of Escherichia coli K-12 as receptors. J. Bacteriol. 1984, 159:724-730.
52. Nishikawa H., Yasuda M., Uchiyama J., Rashel M., Maeda Y., Takemura I., Sugihara S., Ujihara T., Shimizu Y., Shuin T., Matsuzaki S. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections. Arch. Virol. 2008, 153:507-515.
53. O'Flaherty S., Ross R.P., Meaney W., Fitzgerald G.F., Elbreki M.F., Coffey A. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl. Environ. Microbiol. 2005, 71:1836-1842.
54. Petty N.K., Evans T.J., Fineran P.C., Salmond G.P.C. Biotechnological exploitation of bacteriophage research. Trends Biotechnol. 2007, 25:7-15.
55. Plotz P.H., Davis B.D. Synergism between streptomycin and penicillin: A proposed mechanism. Science 1962, 135:1067-1068.
56. Pouillot F., Blois H., Iris F. Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecur. Bioterror. 2010, 8:155-169.
57. Rhoads D.D., Wolcott R.D., Kuskowski M.A., Wolcott B.M., Ward L.S., Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J. Wound Care 2009, 18:237-244.
58. Rivas L., Coffey B., McAuliffe O., McDonnell M.J., Burgess C.M., Coffey A., Ross R.P., Duffy G. In vivo and ex vivo evaluations of bacteriophages e11/2 and e4/1c for use in the control of Escherichia coli O157:H7. Appl. Environ. Microbiol. 2010, 76:7210-7216.
59. Rountree P.M. The serological differentiation of staphylococcal bacteriophages. J. Gen. Microbiol. 1949, 3:164-173.
60. Sanders M.E. Bacteriophages of industrial importance. Phage Ecology 1987, 211-244. John Wiley & Sons, New York. S.M. Goyal, G.P. Gerba, G. Bitton (Eds.).
61. Schackman B.R., Gebo K.A., Walensky R.P., Losina E., Muccio T., Sax P.E., Weinstein M.C., Seage G.R., Moore R.D., Freedberg K.A. The lifetime cost of current human immunodeficiency virus care in the United States. Med. Care 2006, 44:990-997.
62. Skurnik M., Pajunen M., Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol. Lett. 2007, 29:995-1003.
63. Slopek S., Durlakova I., Weber-Dabrowska B., Kucharewicz-Krukowska A., Dabrowski M., Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. 1983, 31:267-291.
64. Sulakvelidze A., Pasternack G.R. Industrial and regulatory issues in bacteriophage applications in food production and processing. Bacteriophages in the Control of Food- and Waterborne Pathogens 2010, ASM Press, Washington, DC. P.M. Sabour, M.W. Griffiths (Eds.).
65. Torella J.P., Chait R., Kishony R. Optimal drug synergy in antimicrobial treatments. PLoS Comput. Biol. 2010, 6:e1000796.
66. Triplitt C. Drug interactions of medications commonly used in diabetes. Diabetes Spectr. 2006, 19:202-2011.
67. Weber-Dabrowska B., Mulczyk M., Górski A. Bacteriophage therapy for infections in cancer patients. Clin. Appl. Immunol. Rev. 2001, 1:131-134.
68. Wright A., Hawkins C.H., Anggård E.E., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009, 34:349-357.